Trials / Not Yet Recruiting

Not Yet RecruitingNCT06766552

A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.

A Multicenter Registry Study Assessing Patient Reported Outcome, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.

Status: Not Yet Recruiting
Phase: —
Study type: Observational
Enrollment: 10,000 (estimated)

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

Ankylosing spondylitis, radiographically negative axial spondyloarthritis, psoriatic arthritis, polymyalgia rheumatica, Takayasu arteritis, giant cell arteritis, non-ocular Behcet's disease, and enthesitis-related arthritis are common diseases in rheumatology. Traditional anti-rheumatic drugs are less effective and have greater side effects than biological agents. At present, there has been no large-scale registration study on rheumatic autoimmune diseases such as spondyloarthritis in China. However, data such as patient characteristics, medication patterns, and patient outcome reports of different rheumatology diseases can often serve as a reference for rheumatology clinicians to reasonably select treatment methods for different patients. Therefore, a large-scale registration study is needed to fill the gap in multi-disease registration studies in rheumatology departments in China.

Conditions

Timeline

Start date: 2025-01-30
Primary completion: 2029-12-30
Completion: 2030-06-30
First posted: 2025-01-09
Last updated: 2025-01-09

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06766552. Inclusion in this directory is not an endorsement.